RE:RE:RE:RE:RE:RE:RE:RE:FTHX HEARTLAND /MY SENTIMENTS EXCATLYHi GV. Normally I use Chrome and that is where I am having problems.
I just switched to Safari because my last post did not go through. Safari seems to be working.
Futility analysis on BETonMACE 2017 should be a mover. Regional deal this year will drive the stock. zen3694 on mCRPC may drive RVX shares and could create very high visibility. Of course success on an orphan trial will be remarkable.
For me the remarkable understanding gained by RVX after ASSURE in the post hoc analysis always reinforces my belief in rvx-208, but not only that, it reinforces my belief in their epigenetic platforms. I don't know when it will happen but I do still believe that Zenith Capital is going to be my money machine through royalties or sales/IPOs of the various zen "Stars" as SF calls them. So here is what RVX says about apabetalone.
From RVX - "Apabetalone (RVX-208) is an orally active small molecule that was discovered in Alberta. It is the first BET inhibitor to enter into human trials for treating CVD. RVX-208 selectively inhibits the second binding domain of BET proteins from complexing with its natural ligand acetylated lysine marks on the tail of histones.
In so doing, RVX-208 modulates gene transcription and has effects on pathways known to play important roles in CVD risks including the complement, coagulation, inflammation, and metabolism as well as increasing levels of the apolipoprotein A-I (apoAI), the major protein in high density lipoprotein(HDL). In addition to preclinical studies in vitro and in vivo, RVX-208 has been tested in many human trials lasting up to 6 months that in total enrolled almost 1000 patients.
In post-hoc analysis of the most recent studies, patients with CVD receiving 200 mg/day of RVX-208 had a 55% relative risk reduction in major adverse cardiac events (MACE) compared to placebo."
The biggest problem Resverlogix had IMHO is that ASSURE was underpowered and the end point...PAV... was not the best choice. However, that was based on the knowledge they had at trial design back in 2011 or so.
The repost I did of Kelsee's feedback from Paradis gave me some reassurance. In particular he indicated that Don's enthusiasm has permeated the science and business teams. If every one of them had skin in the game it would surely enhance innovation and urgency. That being said, this is science and science takes time.
Any victory on any of the trials will drive interest.
However, Don needs to remove barriers by communicating a POV regarding the CL renewal and continued BoM funding (I'm not worried at all).
Yet, the fact that there are no high profile independent analysts covering RVX raises questions.
Anyway, Safari is working for now.
Cheers
Toinv